Skrining CA Serviks

+ Fakultas
Kedokteran
Universitas
Tarumanagara
2018
Cervical Cancer
Disusun oleh : Pembimbing :
Dila Nur Fitriani dr. Hendrik Sutopo,

406172113 M.Biomed, Sp.OG
Kepaniteraan Klinik Obstetrik & Ginekologi

RS Sumber Waras - Jakarta
Periode 11 Maret – 19 Mei 2019

Cervical Cancer
+
 Cervical cancer is the 2nd most common cancer in women
worldwide
 Caused by sexually-acquired infection with Human
papillomavirus (HPV)
 Vaccination against HPV, regular screening, adequate treatment
are key tools to prevent new cervical cancer cases
+
+
Primary prevention:
reduce the risk of HPV infection
Interventions include:
 Vaccinations for girls aged 9–13 years (or the age range
referred to in national guidelines) before they initiate
sexual activity;
 Healthy sexuality education for boys and girls
 Condom promotion or provision for those who are
sexually active
 Male circumcision where relevant and appropriate
+
HPV Vaccines
Protection against high-risk  Both vaccines contain

HPV types 16 and 18 : virus-like particles
(VLPs)
 The bivalent vaccine  vaccines stimulate
(protection against types 16 development of
and 18 only) antibodies
 The quadrivalent vaccine  Quantity of antibodies
(contains additional produced after HPV
protection against types 6 vaccination is greater in
and 11, which are girls below the age of
responsible for 90% of 15 than in girls and
benign anogenital warts or women aged 15 years
condyloma) and older
+ HPV Vaccines
Safety & adverse events Contraindications
 Both vaccines have  Severe allergic reactions

been well tolerated after a previous dose of
 Most common the vaccine
complaints : pain &  Severe febrile illness
swelling at the injection  Pregnant women
site
+ Quadrivalent Vaccines
 HPV types in vaccine 

6,11,16,18
 2 doses, the second dose
6 months after the rst
dose
 intramuscular injection:
0.5 ml of liquid
suspension
Bivalent Vaccines
 HPV types in vaccine 

16,18
 2 doses, the second dose
6 months after the rst
dose
 intramuscular injection:
0.5 ml of liquid
suspension
+ Secondary prevention:
reduce the risk of HPV infection
Screening methods for cervical pre-cancer
 HPV DNA Test

 Visual inspection with acetic acid (VIA)
 Pap smear
 Liquid-based cytology (LBC)
HPV DNA Test VIA
 detection of DNA from high-  inspect the cervix after

risk HPV types in vaginal applying dilute (3–5%)
and/or cervical samples acetic acid
 reserved for women over the  appropriate to use in
age of 30 women whose
 collect a sample of cells by squamocolumnar
inserting a small brush or junction (SCJ) is visible,
other appropriate device typically in those
deep into the vagina younger than 50
+ Secondary Prevention :
Screening And Treatment Of Cervical Pre-cancer
Cytology-based screening
 taking a sample of cells from

the entire transformation zone
 2 available methods: the
conventional Pap smear (or
Pap test) or liquid-based
cytology (LBC)
+
+
+
+
+
+
Diagnostic tests for
detection of cervical
pre-cancer
 Colposcopy
 Biopsy
 Endocervical curettage
Colposcopy
examination of the cervix,

vagina and vulva with an
instrument that provides
strong light and magni es a
eld, allowing specific patterns
in the epithelial (surface)
layer and surrounding blood
vessels to be examined
+
Biopsy
Biopsy is the removal of

small samples of
abnormal tissue for
microscopic examination
to achieve a diagnosis
Endocervical curettage
some surface cells are

gently scraped from the
endocervical canal
+
Treatment options for Cryotherapy
cervical pre-cancer
 eliminates precancerous
 Cryotherapy areas on the cervix by
 Loop electrosurgical excision freezing (an ablative
procedure (LEEP) method)
 Cold knife conization  The supercooling of the
cryoprobe is accomplished
using a tank with
compressed carbon
dioxide (CO2) or nitrous
oxide (N2O) gas
 Eligibility criteria : screen-
positive women,
histologically CIN2+
+Loop electrosurgical
procedure (LEEP)
excision
 removal of abnormal areas

from the cervix using a loop
made of thin wire powered by
an electrosurgical unit
 aims to remove the lesion and
the entire transformation zone
 Eligibility criteria : screen-
positive women, histologically
CIN2+
Cold knife conization
 removal of a cone-shaped
area from the cervix,
including portions of the
outer (ectocervix) and inner
cervix (endocervix
 Eligibility criteria: for cases
that cannot be resolved with
cryotherapy or LEEP
+

Skrining CA Serviks

Uploaded by

Copyright:

Available Formats

Skrining CA Serviks

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Skrining CA Serviks

Uploaded by

Copyright:

Available Formats

+ Fakultas

Disusun oleh : Pembimbing :

Dila Nur Fitriani dr. Hendrik Sutopo,

Kepaniteraan Klinik Obstetrik & Ginekologi

Periode 11 Maret – 19 Mei 2019

Protection against high-risk  Both vaccines contain

Safety & adverse events Contraindications

 Both vaccines have  Severe allergic reactions

 HPV types in vaccine 

 HPV types in vaccine 

Screening methods for cervical pre-cancer

 HPV DNA Test

HPV DNA Test VIA

 detection of DNA from high-  inspect the cervix after

Screening And Treatment Of Cervical Pre-cancer

 taking a sample of cells from

examination of the cervix,

Biopsy is the removal of

some surface cells are

 removal of abnormal areas

Cold knife conization

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.